Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against ABIVAX Societe Anonyme (ABVX) Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - June 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ABIVAX Societe Anonyme ("ABIVAX Societe Anonyme") (NASDAQ: ABVX) concerning potential violations of the federal securities laws.
Abivax shareholders lost more than 40% of their investment value on June 2, 2026, as the stock plunged from a pre-announcement close of approximately $129.69 to as low as $71 per share midday after rare malignancy cases surfaced in the company's Phase 3 ABTECT ulcerative colitis trial for obefazimod. The market reaction was swift and severe. Trading volume surged to more than eight times the daily average on June 2. Jefferies downgraded ABVX from Buy to Hold and cut its price target from $160 to $90 -- a 43.75% reduction -- citing the cancer signal as a material overhang on the stock's outlook. Short interest climbed to approximately 12% of the float within 24 hours of the disclosure.
Notably, the stock had initially rallied approximately 20% in after-hours trading on June 1 when the Phase 3 efficacy data were first released. Within hours, as the rare malignancy cases in the treatment arm received broader coverage, the rally reversed entirely and shares collapsed through the prior close. By the midday trading on June 2, ABVX had fallen more than 45%, erasing all gains since mid-August, 2025.
If you suffered a loss on your ABIVAX Societe Anonyme securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300241
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against ABIVAX Societe Anonyme (ABVX)
2026-06-04 3:24 PM EDT
Levi & Korsinsky Investigates Shake Shack Inc. (SHAK) Over Potential Securities Fraud Allegations
2026-06-04 3:23 PM EDT
OCS ALERT: Levi & Korsinsky Investigates Oculis Holding AG for Possible Securities Fraud Violations
2026-06-01 12:05 PM EDT
Jan 22, 2026
UPDATE: On March 5, the SEC issued an Exemptive Order (Release No. 34-104931) providing significant relief for FPIs in "qualifying jurisdictions," including Canada . Because the SEC now recognizes Canada’s reporting standards as "substantially similar," most Canadian directors and officers are exempt from the Section 16(a) filings described below. However, this relief depends on the jurisdiction of incorporation; FPIs incorporated in "offshore" jurisdictions (e.g., Cayman Islands or BVI)...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services